Holen Sie sich die Stockscreener-App
2.55
0.78%
-0.02
Handel nachbörslich:
2.52
-0.03
-1.18%
Schlusskurs vom Vortag:
$2.57
Offen:
$2.57
24-Stunden-Volumen:
139.93K
Relative Volume:
0.23
Marktkapitalisierung:
$143.67M
Einnahmen:
$76.19M
Nettoeinkommen (Verlust:
$-1.61M
KGV:
255.00
EPS:
0.01
Netto-Cashflow:
$28.98M
1W Leistung:
+8.51%
1M Leistung:
+9.44%
6M Leistung:
-16.12%
1J Leistung:
+155.00%
1-Tages-Spanne:
$2.52
$2.57
1-Wochen-Bereich:
$2.3791
$2.655
52-Wochen-Spanne:
$0.5052
$3.22
Spero Therapeutics Inc Stock (SPRO) Company Profile
Firmenname
Spero Therapeutics Inc
Sektor
Branche
Telefon
857-242-1600
Adresse
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Vergleichen Sie SPRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.55 | 144.79M | 76.19M | -1.61M | 28.98M | 0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-23 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-10-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-01-22 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-09-29 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-09-09 | Eingeleitet | Janney | Buy |
| 2018-02-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-11-27 | Eingeleitet | BofA/Merrill | Neutral |
| 2017-11-27 | Eingeleitet | Oppenheimer | Outperform |
| 2017-11-27 | Eingeleitet | Stifel | Buy |
Alle ansehen
Spero Therapeutics Inc Aktie (SPRO) Neueste Nachrichten
Will Spero Therapeutics Inc. stock benefit from upcoming earnings reports2025 Trade Ideas & Free Expert Verified Stock Movement Alerts - ulpravda.ru
Will Spero Therapeutics Inc. (2HA) stock sustain bullish trend into 2025Quarterly Earnings Summary & AI Forecast for Swing Trade Picks - ulpravda.ru
Spero Therapeutics (NASDAQ:SPRO) Downgraded by Wall Street Zen to Hold - MarketBeat
What analysts say about Spero Therapeutics Inc stockLong-Term Growth Stocks & Free Unmatched Market Gains - earlytimes.in
Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200-Day Moving Average – Here’s What Happened - Defense World
Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200-Day Moving AverageHere's What Happened - MarketBeat
Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Large Growth in Short Interest - MarketBeat
Book value per share of Spero Therapeutics, Inc. – BER:2HA - TradingView — Track All Markets
Spero Therapeutics (STU:2HA) EV-to-OCF : -2.75 (As of Dec. 24, 2025) - GuruFocus
Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200 Day Moving AverageTime to Sell? - MarketBeat
Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200 Day Moving Average – Time to Sell? - Defense World
Will Spero Therapeutics Inc. stock reach all time highs in 2025Inflation Watch & Growth Oriented Trade Recommendations - Улправда
Stop Loss: Will Spero Therapeutics Inc. stock reach all time highs in 2025Inflation Watch & Reliable Price Breakout Signals - ulpravda.ru
GSK, Spero Therapeutics resubmits NDA for tebipenem HBr as oral option for complicated urinary tract infections - Contemporary OB/GYN
GSK Resubmits NDA, Triggering Milestone for Spero Therapeutics - TipRanks
Spero Therapeutics Announces NDA Resubmission for Tebipenem HBr - TradingView — Track All Markets
Spero Therapeutics Announces GSK's NDA Resubmission for Tebipenem HBr, Triggering $25 Million Milestone Payment - Quiver Quantitative
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to - GlobeNewswire
How geopolitical risks impact Spero Therapeutics Inc. (2HA) stockMarket Performance Report & Short-Term Trading Opportunity Alerts - DonanımHaber
Total debt per share of Spero Therapeutics, Inc. – FWB:2HA - TradingView — Track All Markets
Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Spero Therapeutics (SPRO) price target decreased by 20.00% to 4.08 - MSN
Spero Therapeutics (NASDAQ:SPRO) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Spero Therapeutics (NASDAQ:SPRO) Stock Rating Lowered by Wall Street Zen - MarketBeat
Can Spero Therapeutics Inc. (2HA) stock test all time highsMarket Risk Report & Free Low Drawdown Momentum Trade Ideas - Newser
Will Spero Therapeutics Inc. (2HA) stock benefit from sector leadership2025 Top Gainers & Free Weekly Watchlist of Top Performers - Newser
Why Spero Therapeutics Inc. stock is popular among millennials2025 Market Overview & Community Consensus Picks - Newser
How Spero Therapeutics Inc. (2HA) stock behaves in tightening cycles2025 Trading Recap & Intraday High Probability Alerts - Newser
How Spero Therapeutics Inc. stock benefits from global expansionStock Surge & Risk Adjusted Buy/Sell Alerts - Newser
How Spero Therapeutics Inc. (2HA) stock performs during market turbulenceJuly 2025 Reactions & Short-Term High Return Strategies - Newser
Published on: 2025-12-02 04:03:46 - Newser
Will Spero Therapeutics Inc. (2HA) stock remain on Wall Street radar2025 Price Momentum & Reliable Volume Spike Trade Alerts - Newser
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates - MSN
Spero Therapeutics announces inducement grant under Nasdaq listing rule - MSN
Spero Therapeutics (NASDAQ:SPRO) Upgraded to “Buy” at Wall Street Zen - Defense World
Can Silver Oak India Limited Maintain Its Share of Global Market for Its ProductStock Buy Signals & Get Free Training on Technical Indicators - earlytimes.in
Spero Therapeutics (SPRO) Awards New Employee with Restricted St - GuruFocus
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Enidnews.com
Breakout Move: Will Spero Therapeutics Inc. stock reach all time highs in 2025 - moha.gov.vn
Aug Mood: Will Spero Therapeutics Inc. stock reach all time highs in 2025July 2025 Patterns & AI Forecasted Entry and Exit Points - moha.gov.vn
Spero Therapeutics (NASDAQ:SPRO) Shares Cross Above 200-Day Moving Average – Should You Sell? - Defense World
Global NTM Infections Pipeline Poised for Growth as Breakthrough Therapies Advance Toward Late-Stage Development, states DelveInsight - The Globe and Mail
What is Spero Therapeutics Inc (SPRO) Stock Return on Shareholders’ Capital? - Setenews
Why Spero Therapeutics Inc. (2HA) stock is favored by hedge fundsJuly 2025 Final Week & Free Weekly Chart Analysis and Trade Guides - newser.com
Will Spero Therapeutics Inc. stock attract ESG investorsWeekly Trade Recap & Verified Swing Trading Watchlists - newser.com
How Spero Therapeutics Inc. (2HA) stock reacts to stronger dollarBear Alert & Low Drawdown Momentum Trade Ideas - newser.com
Finanzdaten der Spero Therapeutics Inc-Aktie (SPRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spero Therapeutics Inc-Aktie (SPRO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mahadevia Ankit | Director |
Aug 28 '25 |
Sale |
1.97 |
6,572 |
12,947 |
703,294 |
| Keutzer Timothy | Chief Operating Officer |
Aug 28 '25 |
Sale |
1.97 |
1,695 |
3,339 |
739,744 |
| Keutzer Timothy | Chief Operating Officer |
Feb 05 '25 |
Sale |
0.78 |
56,537 |
44,099 |
741,439 |
| Rajavelu Esther | CFO & CBO |
Feb 05 '25 |
Sale |
0.78 |
20,689 |
16,137 |
724,720 |
| Shukla Sath | CEO & President |
Feb 05 '25 |
Sale |
0.78 |
155,333 |
121,160 |
1,736,883 |
| Mahadevia Ankit | Director |
Feb 05 '25 |
Sale |
0.78 |
69,219 |
53,991 |
689,866 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):